A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...

In the latest close session, Amgen (AMGN) was up +1.69% at $355.30. This move outpaced the S&P 500's daily gain of 1.2%. Elsewhere, the Dow gained 1.79%, while the tech-heavy Nasdaq added 1.52%. Prior ...

Amgen Inc. (NASDAQ:AMGN) is included among the 10 Healthcare Stocks with Highest Dividends. On April 13, UBS lifted its price ...

The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.

Amgen and Zai Lab have agreed to run a global clinical trial combining two DLL3 targeted therapies for small cell lung cancer ...

Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.

Zai Lab (ZLAB) stock jumps as the company announces a global clinical trial collaboration with Amgen (AMGN). Read more here.

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. New data from a mid-stage study of an Amgen obesity drug showed that it ...

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...

The findings could help Amgen defend Tepezza’s market-leading position against emerging rivals, though some analysts ...

Evidence gaps include limited topline safety granularity, unknown long-term follow-up and retreatment rates, and lack of ...